Patients with mantle cell lymphoma (MCL) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high-dose therapy with autologous stem cell support has resulted in 10-year overall survival (OS) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the MCL International Prognostic Index (MIPI), gene expression-based proliferation signature, Ki-67 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring-based RNA expression-based proliferation assay (MCL35) on formalin-fixed paraffin-embedded tumour tissue from younger patients recruited in or treated according to Nordic MCL protocols compared to the prognosticators listed above. Seventy-four patients were included and the assay performed well in all cases except four, which had inadequate RNA quality. The patients were evenly distributed in the MCL35 low-, intermediate-and high-risk categories. MCL35 low-and intermediate-risk groups had overlapping progression-free survival (PFS), while patients in the high-risk category had significantly inferior PFS. Combining MCL35 with MIPI or the MIPI-C (MIPI with the addition of binary Ki67 score +/À30%) showed a better discrimination than either assessment alone. In conclusion, the MCL35 assay alone or combined with MIPI or MIPI-C scores can identify patients who still have a dismal outcome despite intensified treatment.
Mantle cell lymphoma (MCL) is an aggressive disease with poor overall survival (OS). Although new intensive treatment regimens have improved survival, there is no indication that the disease can be cured with standard treatments Kluin-Nelemans et al, 2012; Abrahamsson et al, 2014; Dreyling et al, 2014; Kolstad et al, 2014) . The outcome is variable, but clinical factors can discern between prognostic groups based on age, performance status, lactate dehydrogenase (LDH) level, and leucocyte count, when combined as the MCL International Prognostic Index (MIPI) .
Microarray RNA expression analyses, pioneered by the National Cancer Institute and the Leukemia and Lymphoma Molecular Profiling Project (LLMPP), have expanded the diagnostic accuracy in malignant lymphomas and have identified a proliferation signature as a strong predictor of survival in MCL (Rosenwald et al, 2003) . However, gene expression analyses were performed on fresh frozen tissue, which is not readily available for the majority of patients. To translate these findings to clinical practice, a tumour cell proliferation index, based on Ki-67 staining by immunohistochemistry (IHC) has been tested and recognized as a strong adverse prognostic factor (Raty et al, 2002; Tiemann et al, 2005; Katzenberger et al, 2006; Determann et al, 2008; Hoster et al, 2014 Hoster et al, , 2016 , and was the only biological factor at diagnosis with predictive power in multivariate analysis in a Nordic prospective phase II study . However, several studies on IHC analysis in lymphoma, including MCL, have shown large inter-observer variability, which poses a challenge for comparison of results between laboratories (De Jong et al, 2007; Klapper et al, 2009; Sander et al, 2014) . Therefore, a standardization of IHC evaluation of Ki-67 index in MCL is recommended (Klapper et al, 2009; Dreyling et al, 2013 ).
An assay using Nanostring â technology to measure RNA expression of a selected number of genes extracted from formalin-fixed, paraffin-embedded tissue (FFPE) has been developed (Roberts et al, 2007) . This technology has been applied to discern between the two major subtypes of diffuse large B-cell lymphomas, activated B cell-like and germinal centre B cell-like (Scott et al, 2014 ). An assay which applies the same technology has been developed for MCL by selecting 35 different genes, of which 17 were associated with proliferation and 18 were housekeeping genes. The MCL35 assay stratified patients into high-, standard-and low risk in a training set of 47 biopsies and was validated in a separate cohort of 110 patients (Scott et al, 2017) . The validation cohort originated from British Columbia and consisted of patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) chemoimmunotherapy. Of note, in approximately half the patients, there was an intention to consolidate with high dose chemotherapy and autologous stem cell transplantation (HD-ASCT). In this study, the pretreatment biopsies contained at least 60% tumour cells and were excisional nodal biopsies. For the above assay to be recommended in routine clinical practice, it should also be validated in a separate cohort of patients who have been treated with a regimen that now is considered to be standard for younger patients: alternating R-CHOP with a R-HDAC rituximabhigh dose cytarabine -containing regimen (total of 6 courses) followed by HD-ASCT. We have, therefore, tested the MCL35 assay on a cohort of Norwegian patients, recruited in two Nordic clinical trials, MCL2 and MCL3 Kolstad et al, 2014) , or treated accordingly after closure of the trials.
Methods

Patients and material
All Norwegian patients diagnosed with MCL with available FFPE diagnostic material and who had been treated in two consecutive Nordic phase II trials (MCL2 and MCL3) or according to the MCL2 protocol were eligible for this study -153 cases in total. Danish and Swedish patients were not included. Further selection of patients was performed according to the Consort diagram ( Figure S1 ). Only surgical material from lymph nodes or Waldeyer ring and with at least 60% tumour infiltration was considered suitable. Thus, out of 153 cases, 78 were deemed suitable for the MCL35 assay.
The study was approved by Regional Committee for Medical and Health Research Ethics South East (reg. no. 2016/1459) and by the Protection Officer at Oslo University Hospital.
RNA extraction and gene expression profiling
Unstained sections from FFPE tissue (1-2 slides if the surface area was >1 cm 2 , 5 slides for 0Á1-1 cm 2 and 10 slides for <0Á1 cm 2 ) were sent to Vancouver for deparaffinization with the QIAGEN Deparaffinization Solution and RNA extraction with the QIAGEN AllPrep DNA/ RNA FFPE Kit (both QIAGEN GmbH, Hilden, Germany). The RNA was quantified with spectrophotometry (NanoDrop, ThermoFisher Scientific, Waltham, MA, USA). The MCL35 assay was performed on a minimum of 200 ng of RNA on NanoString technology (NanoString Technologies, Seattle, WA, USA) as previously described (Scott et al, 2014) .
Pathology
Biopsies from patients included in the Nordic MCL2 and MCL3 studies or treated after closure of the Nordic MCL studies according to the MCL2 protocol were reviewed. Only biopsy samples originating from a lymph node or Waldeyer ring, fulfilling the histological and immunohistochemical criteria established by the World Health Organization (WHO) (Swerdlow et al 2017) for the diagnosis of MCL and containing ≥60% tumour cells were selected for this study. Following WHO criteria (Swerdlow et al 2017) , tumours were subclassified into those with blastoid/pleomorphic (referred to as blastic) and those with classical histology. Ki-67 score was calculated as an average percentage of positive cells after counting immunohistochemically positive cells in representative tumour areas by an experienced pathologist.
Statistics
The chi square or Fisher tests were applied to examine differences in patient characteristics between MCL35 risk categories. The primary endpoint was OS, which was calculated from date of diagnosis or inclusion in prospective studies until date of death from any cause. Secondary end point was progression-free survival (PFS), calculated from date of diagnosis or study until date of progression or death from any cause (Cheson et al, 2007) . OS and PFS were estimated using the Kaplan-Meier method. Log-rank test was used to examine the relationship between categorical variables and OS or PFS. Univariable analyses using Cox models were used to examine the relationship between defined variables and OS, including continuous variables.
Cox proportional hazards regression tests were used to test the association of variables with OS in combination with other variables. Two-sided P values <0Á05 were considered significant. (92) 26 (96) 27 (93) 15 (
59 (80) 24 (89) 19 (66) 16 (89) 0Á051 LDH Normal 35 (47) 16 (59) 15 (52) 4 (25) 0Á043 >ULN 39 (53) 11 (41) 14 (48) 14 (75) MIPI Low (<5Á7) 36 (49) 15 (56) 14 (48) 7 (39) 0Á81 Intermediate (5Á7-6Á2)
26 (35) 9 (33) 10 (35) 7 (39) High (>6Á2) 12 (16) 3 (11) 5 (17) 4 (27) MIPI -C Low 25 (34) 13 (48) 10 (35) 
Results
Description of patient material
The MCL35 assay was applied to the biopsies of 78 patients, with 74 (95%) passing quality control. The assay assigned 27 (36%), 29 (39%) and 18 (24%) of the patients to low-, standard-and high-risk MCL35 categories, (thresholds À143 and À28) respectively. The median MCL35 value was À113Á05 (range À303Á6-+129Á9). The demographic data, disease characteristics and treatments of all 74 MCL patients with MCL35 score (Scott et al, 2017) are shown in Table I . There was a male predominance and the median age was 59 years, most patients had Eastern cooperative Oncology Group (ECOG) performance status 0-1 and bone marrow infiltration, and the distribution of MIPI and MIPI-C (MIPI with the addition of binary Ki67 score +/À30% risk; Hoster et al, 2016) was as expected. There was an even distribution of Ki-67 score (classified as <30% or >30%). A quarter of the biopsies were of blastic (blastoid or pleomorphic) morphology. Of note, the majority of patients completed the intended treatment with alternating R-Maxi CHOP/R-HDAC and consolidation with HD-ASCT. The median observation time was 5Á3 years, there were no missing data in the final cohort and no patients were lost to follow-up.
Distribution of patient and tumour characteristics across MCL35 risk groups Figure 1 shows the heat map of RNA expression of the 35 genes (rows) for the 74 cases included in the analyses (columns). Underneath is depicted the corresponding Ki-67 dichotomized score, MIPI score and histology (blastic versus classical). Table I shows the baseline distribution of disease characteristics across the three MCL35 risk groups. There were significant correlations between MCL35 risk groups and elevated LDH level (P = 0Á043), blastic histology (P < 0Á001) and Ki-67 score >30% (P < 0Á001) (Table I ; Fig 2A, B) , but no significant correlations to MIPI (Table I , Fig 2C) , MIPI-B (MIPI with the addition of Ki67 score <10%, ≥10-29% or ≥30%; Hoster et al, 2014) or MIPI-C (Table I) .
Survival prediction for risk factors
The median observation time for all patients was 5Á2 years (range 0Á5-13Á7). The estimated 5-year OS and PFS was 77% and 60%, respectively, and 60% and 48% at 10 years ( Fig 3A, B) . Patients with Ki-67 ≥30% and blastic morphology (Fig 3C, D) had an inferior survival. Compared with data in the original manuscript (Scott et al, 2017) , low-and standard-risk groups did not have significantly different outcomes, while the high-risk group had inferior outcome (Fig 3E, F) . MIPI and MIPI-C discriminated well between the different risk categories (Fig 4A-D) . In Cox unadjusted analysis, LDH level (normal versus elevated), ECOG performance status (0-1 vs. 2-4), Ki-67 5% incremental up to 30%, Ki-67 +/À 30%, MIPI Score, MIPI-C score and MCL35 score predicted OS and PFS (albeit the MCL35 score was only of borderline significance for PFS; Table II ). In Cox adjusted multivariate analysis including Ki-67% with 5% increments and MCL35, only Ki-67 was significant for OS and PFS. However, when Ki-67 was included as a dichotomized variable (≥ vs. <30%), neither were associated with survival (Table II) . When MIPI and MCL35 were included in multivariable analysis, both variables were associated with OS, but with the MIPI score showing a better survival prediction (Table II) . Lastly, in multivariable analysis including MCL35, Ki-67 and MIPI, the two latter variables were significantly associated with OS and PFS. Unadjusted analyses of MCL35 score (standard versus low and high versus low) and adjusted multivariate analysis of the same variables, including Ki-67 and MIPI score, is shown in Table S1 . As MCL35 score did not correlate with the MIPI scores, there was a rationale for combining the MCL35 scores with MIPI scores in an exploratory analysis. When combining high risk MCL35 with high risk MIPI, we identified six patients with a very high risk (Fig 4E) , and when combining with high or high intermediate MIPI-C, we identified 12 patients with substantially inferior survival (Fig 4F) . Unadjusted and adjusted analyses of MCL35 and MIPI for Ki-67 are shown in Table S2 .
Discussion
The intention of the current analysis was to test the ability of the MCL35 assay to predict survival in a cohort of MCL patients younger than 70 years treated with alternate R-MaxiCHOP/R-HDAC and HD-ASCT (BEAM: carmustine, etoposide, cytarabine, melphalan). The estimated 5-year OS of 77% was comparable to that reported from two Nordic MCL studies where the patients received a similar regimen Kolstad et al, 2014) and with no plateaus in the survival curves. The overall outcome was superior to that shown in the original report on the MCL35 assay (Scott et al, 2017) , where the patients received R-CHOP and only around half of them were consolidated with HD-ASCT. The outcome for our total cohort was comparable to that of the MCL35 low risk group in the original report. This justifies our evaluation of the performance of the MCL35 assay in a patient cohort of younger patients treated with, what is now considered to be, standard of care. While in the original publication there was a very clear discrimination among three risk groups (Scott et al, 2017) , the MCL35 assay did not separate the standard-risk group from the low-risk group in our cohort. However, the MCL35 assay was able to identify a subgroup with inferior outcome despite treatment with intensified chemo-immunotherapy and HD-ASCT therapy. This indicates that survival was improved, especially for patients in the MCL35 standard-risk upon introduction of current intensified treatment regimens.
When comparing the predictive value of the assay relative to MIPI and MIPI-C in our cohort, the MIPI scores provided improved stratification compared to the MCL35 assay. Similarly, Ki-67 score (≥ vs. <30%) alone and histology (blastic versus classical) stratified patient outcome better than the MCL35 assay. However, there is still a rationale to use the MCL35 assay in risk stratification: the MIPI score identifies clinical risk factors only and was not correlated to MCL35 scores. In addition, the Ki-67 score included in the MIPI-C prognostic index is difficult to assess in routine clinical practice and has shown considerable inter-observer variability (De Jong et al, 2007; Klapper et al, 2009 Sander et al, 2014 , although the reproducibility can be improved by standardizing the IHC evaluation (Klapper et al, 2009; Dreyling et al, 2013) . In comparison, the MCL35 assay has been shown to have a good reproducibility across different centres (Scott et al, 2017) . The data suggest that the prognostic effect of the MCL35 assay is independent of clinical factors, but it remains unclear whether its prognostic value is comparable to the Ki-67 index. A future comparative analysis of MCL35 and Ki-67 index using a larger patient cohort is warranted to clarify whether the presumed higher reproducibility of the MCL35 score is at the expense of lower prognostic value. Further, there is a need for validation of our findings in a separate and larger, but similarly treated patient cohort. A combination of MIPI score and MCL35 score is plausible for taking into account both clinical and biological risk factors. When combining high-risk MCL35 with high-risk MIPI score, we identified a smaller subgroup with dismal prognosis. Such patients should probably not receive standard treatment but rather be recruited to up-front clinical trials with novel investigational drugs like ibrutinib, lenalidomide and venetoclax as single agents or in combination with other drugs (Wang et al, 2013 (Wang et al, , 2016 Dreyling et al, 2016; Trneny et al, 2016; Davids et al, 2017) . Indeed, both clinical and biological risk factors have to be assessed when new therapeutic approaches are introduced.
Novel biological risk factors have been identified during recent years like non-functional TP53 through genetic loss of p17 or mutations (Eskelund et al, 2017; Aukema et al, 2018) for identifying patients with inferior outcome.
Strengths of this study include that patients were uniformly treated and the fact that there were no missing values for any of the variables. Furthermore, the MCL35 analysis was performed by the group who developed the assay. For two patients, who were ultimately excluded from the study, results of the MCL35 assay did not fit with what was expected for a MCL biopsy. A second review of the diagnosis in these cases revealed that MCL could not be confirmed in one patient and for the other patient the sample was massively necrotic (data not shown) resulting in a viable tumour content of <60%. Thus, the assay, although developed for predictive purposes, might also be of diagnostic value.
A weakness of this study is the limited sample size which reduces the power of the analyses. Additionally, the assay was developed for surgical biopsies from lymph nodes with tumour content of at least 60%, excluding samples from bone marrow and non-lymphoid tissue. However, OS and PFS at 5 and 10 years are nearly identical to those published for the whole cohort of Nordic patients included in the MCL2 and MCL3 studies (Kolstad et al, 2014) . Nevertheless, the MCL35 assay remains to be validated in samples that do not meet these criteria as this, so far, reduces the applicability of the assay.
In conclusion, the MCL35 assay was able to identify a group of MCL patients with inferior outcome after intensive first-line treatment, including HD-ASCT, but standard-and low-risk groups had similar outcomes. By combining MIPI or MIPI-C and MCL35, patients with dismal prognosis were identified, and these patients should be considered for novel strategies.
Author contribution
HH, AK, EBS, DWS, LMR and AR designed the research study; HH, KB, MB, SK, YNB, GT performed the research; HH and OCL analysed the data. HH, JM and AK wrote the paper. All co-authors contributed and accepted the manuscript.
Conflict of interest statement
Andreas Rosenwald, Lisa M. Rimsza, Erlend B Smeland and David W. Scott are named inventors on two patents filed by the National Cancer Institute: 'Methods for selecting and treating lymphoma types' licensed to NanoString Technologies, and 'Evaluation of mantle cell lymphoma and methods related thereof.' Harald Holte is named inventor on one patent filed by the National Cancer Institute: 'Methods for selecting and treating lymphoma types' licensed to NanoString Technologies.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Fig S1. Consort diagram. Selection of Norwegian MCL patients for the MCL35 assay. Table S1 . Prognostic value of MCL35 score (low -standard -high), MIPI and Ki67 score for overall and progression free survival. Table S2 . Prognostic value of MCL35 score combined with MIPI, Ki-67 and MIPI-C score for overall and progression free survival.
